LakeShore Biopharma Co., Ltd (“LakeShore Biopharma” or the “Company”) (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, announces that it has entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Oceanpine Skyline Inc. (“Parent”) and Oceanpine Merger Sub Inc. (“Merger Sub”), a wholly owned subsidiary of Parent, in a transaction implying an equity value of the Company of approximately US$37 million.
Read the full article: LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction //
Source: https://www.prnewswire.com/news-releases/lakeshore-biopharma-enters-into-definitive-agreement-for-going-private-transaction-302603988.html